# Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

> **NCT03258047** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 60 (estimated)

## Conditions studied

- B Cell Lymphoma

## Interventions

- **COMBINATION_PRODUCT:** CAR-T

## Key facts

- **NCT ID:** NCT03258047
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-15
- **Primary completion:** 2019-01-13
- **Final completion:** 2019-07-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258047, "Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03258047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*